Response and resistance factor candidates to HER2 targeted therapy in gastric cancer (GC)

被引：0
|
作者：
Lordick, F. [1 ]
Haffner, I. [1 ]
Luber, B. [2 ]
Maier, D. [3 ]
Kretzschmar, A. [4 ]
von Weikersthal, L. Fischer [5 ]
Riera-Knorrenschild, J. [6 ]
Ahlborn, M. [7 ]
Schierle, K. [8 ]
Wittekind, C. [8 ]
机构：
[1] Univ Hosp Leipzig, Univ Canc Ctr Leipzig, Leipzig, Germany
[2] Tech Univ Munich, Munich, Germany
[3] Biomax Informat AG, Planegg, Germany
[4] MVZ Mitte Onkol Schwerpunktpraxis, Leipzig, Germany
[5] Gesundheitszentrum St Marien GmbH, Dept Oncol, Amberg, Germany
[6] Univ Klinikum Giessen & Marburg, Marburg, Germany
[7] Klinikum Braunschweig, Braunschweig, Germany
[8] Univ Hosp Leipzig, Pathol, Leipzig, Germany
来源：
ANNALS OF ONCOLOGY | 2016年 / 27卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PD-005
引用
收藏
页码：103 / 103
页数：1
相关论文
共 50 条
  • [1] Clinical validation of response and resistance factor candidates to targeted therapy in gastric cancer (GC)
    Haffner, I
    Luber, B.
    Maier, D.
    Geier, B.
    Kretzschmar, A.
    von Weikersthal, Fischer L.
    Ahlbom, M.
    Knorrenschild, Riera J.
    Rau, B.
    Weissinger, F.
    Fuxius, S.
    Neumann, S.
    Decker, T.
    Schierle, K.
    Wittekind, C.
    Lordick, F.
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 316 - 316
  • [2] Clinical validation of response and resistance factor candidates to targeted therapy in gastric cancer (GC)
    Haffner, I.
    Luber, B.
    Maier, D.
    Geier, B.
    Theis, F.
    Meyer-Hermann, M.
    Walch, A.
    Kretzschmar, A.
    von Weikersthal, L. Fischer
    Knorrenschild, J. Riera
    Schierle, K.
    Wittekind, C.
    Lordick, F.
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 16 - 17
  • [3] Recent advances in the HER2 targeted therapy of gastric cancer
    Matsuoka, Tasuku
    Yashiro, Masakazu
    WORLD JOURNAL OF CLINICAL CASES, 2015, 3 (01) : 42 - 51
  • [4] Recent advances in the HER2 targeted therapy of gastric cancer
    Tasuku Matsuoka
    Masakazu Yashiro
    World Journal of Clinical Cases, 2015, (01) : 42 - 51
  • [5] HER2 Testing and Targeted Therapy in Advanced Gastric Cancer
    Hoehler, Thomas
    Rueschoff, Josef
    Ridwelski, Karsten
    Moehler, Markus
    ONKOLOGIE, 2010, 33 : 26 - 30
  • [6] HER2 positive gastric cancer: Who benefits from HER2 targeted therapy?
    Kolbe, K.
    Haffner, I.
    Schierle, K.
    Maier, D.
    Geier, B.
    Luber, B.
    Kretzschmar, A.
    von Weikersthal, Fischer L.
    Ahlborn, M.
    Riera, J.
    Rau, B.
    Siegler, G.
    Fuxius, S.
    Decker, T.
    Wittekind, C.
    Lordick, F.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 156 - 157
  • [7] HER2 targeted therapy: Determinants of response and mechanisms of resistance
    Schiff, R.
    Veeraraghavan, J.
    De Angelis, C.
    Osborne, C.
    Rimawi, M. F.
    CANCER RESEARCH, 2021, 81 (04)
  • [8] HER2 targeted alpha therapy against metastasis of gastric cancer
    Li, Huizi K.
    Hasegawa, Sumitaka
    CANCER SCIENCE, 2022, 113
  • [9] Targeted HER2 Treatment in Advanced Gastric Cancer
    Jorgensen, Jan Trost
    ONCOLOGY, 2010, 78 (01) : 26 - 33
  • [10] HER2 protein quantification in multiple cancer indications identifies candidates for HER2 targeted therapies
    Sellappan, Shankar
    Schwartz, Sarit
    Wertheimer, Ellen
    Cecchi, Fabiola
    Mamus, Steven W.
    Catenacci, Daniel V. T.
    Hembrough, Todd
    CANCER RESEARCH, 2017, 77
12345